AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.99
+0.01 (+1.02%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.98
Open0.98
Bid0.75 x 1100
Ask1.15 x 2400
Day's Range0.96 - 1.01
52 Week Range0.79 - 5.17
Volume196,421
Avg. Volume657,531
Market Cap14.945M
Beta1.51
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What Investors Should Know About Aethlon Medical Inc’s (AEMD) Financial Strength
    Simply Wall St.21 days ago

    What Investors Should Know About Aethlon Medical Inc’s (AEMD) Financial Strength

    While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of USD $14.62M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • Zacks Small Cap Researchlast month

    AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway

    Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018.  Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike).  AEMD expects current cash (i.e.

  • How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?
    Simply Wall St.2 months ago

    How Does Aethlon Medical Inc (AEMD)’s Prospect Stack Up Next To Its Healthcare Peers?

    Aethlon Medical Inc (NASDAQ:AEMD), a USD$14.64M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • Should You Have Aethlon Medical Inc’s (AEMD) In Your Portfolio?
    Simply Wall St.3 months ago

    Should You Have Aethlon Medical Inc’s (AEMD) In Your Portfolio?

    If you are looking to invest in Aethlon Medical Inc’s (NASDAQ:AEMD), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Zacks Small Cap Research4 months ago

    AEMD: EAP Filed, Expect FDA Response By Mid-September

    The major highlight on the operational front since our last update (on June 30th) was submission of the anticipated application to FDA seeking EAP designation for the Hemopurifier.  In an 8-K, filed earlier this week, Aethlon disclosed that they received formal receipt from the FDA of their EAP submission.  Per FDA guidance, the agency’s goal is to make a decision within 30 days (~mid-September) whether to grant EAP designation, or in the event additional information is required, to formally request that the sponsor (i.e.

  • Forbes4 months ago

    Former NFL Pro Supports Study Of Brain Injuries And Dementia In Football

    James Joyce, who played football for the Denver Broncos, is now supporting biotech research aimed at answering questions about the link between repeated head blows and dementia.

  • Capital Cube4 months ago

    ETFs with exposure to Aethlon Medical, Inc. : August 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Aethlon Medical, Inc. : July 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Research5 months ago

    AEMD: Feasibility Study Validates Capture, EAP FDA Filing Is Next

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q4 2017 Financials, Operational Update… Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal fourth quarter 2017 ending March 31st and provided ...

  • Aethlon Medical, Inc. :AEMD-US: Earnings Analysis: 2017 By the Numbers : June 30, 2017
    Capital Cube5 months ago

    Aethlon Medical, Inc. :AEMD-US: Earnings Analysis: 2017 By the Numbers : June 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Aethlon Medical, Inc. reports financial results for the year ended March 31, 2017. Highlights Change in operating cash flow of 19.02% compared to same period last year is about the same as change in earnings, likely no significant movement in accruals or reserves. Narrowing of operating margins contributed to decline in ... Read more (Read more...)

  • Zacks Small Cap Research7 months ago

    AEMD: Feasibility Study Complete. FDA Discussions Expected To Follow

    Operational Update:  Feasibility Study Done, Safety Appears Non-Issue. In mid-March AEMD announced the completion of their U.S. feasibility study.  While expected to enroll 10 subjects, final enrollment was 8 patients with ESRD or HCV – which the company deemed sufficient given no evidence of treatment-related adverse events (i.e.

  • Zacks Small Cap Research10 months ago

    AEMD: FDA Discussions Regarding U.S. Clearance Pathway

    Aethlon (AEMD) reported financial results for their fiscal third quarter 2017 (ending December 2016) and provided an operational update.  There were no meaningful surprises in the financial results relative to our expectations with the top-line ($0 A vs. $8k E), operating expenses ($1.2M A vs. $1.3M E), net loss ($1.2M A vs. $1.3M E) and EPS (-$0.15 A vs. -$0.16) E) all coming in just about exactly where we had modeled. Relative to the balance sheet, AEMD exited fiscal Q3 with $628k cash and equivalents.  They raised $288k and $578k (net) from the sale of equity (via ATM) and convertible notes, respectively, during the quarter.  Subsequent to quarter-end, AEMD raised an additional $256k (net) via the sale of 64k common shares @ $3.98/share average through their ATM program.  Aethlon raised ~$810k through the ATM program since the beginning of Q2 and there remains ~$11M still available.

  • Zacks Small Cap Research10 months ago

    AEMD: New CTE Study Largest in Ex-NFL Players

    Following conclusion of the DARPA DLT sepsis-related program, Aethlon (AEMD) wasted little time in allocating its focus on other high-priority programs, including further validation of Hemopurifier in the capture of certain viruses and pathogens  - progress which could lead towards eventually utility of the device in a variety applications including as a broad spectrum countermeasure against viral pathogens – an objective which also aligned with the Public Health Emergency Medical Countermeasures Enterprise’s (PHEMCE) goal of developing broad-spectrum medical countermeasures (MCM).  The company also continues to move forward on other applications of Hemopurifier, including potentially in sepsis.

  • Aethlon Medical Inc. (AEMD) Readies CTE Blood Diagnostic Trial As Super Bowl LI Approaches
    Insider Monkey11 months ago

    Aethlon Medical Inc. (AEMD) Readies CTE Blood Diagnostic Trial As Super Bowl LI Approaches

    Super Bowl season is upon us, and every year more and more focus this time of year gets placed on a brain disease known as chronic traumatic encephalopathy (CTE). It is a disease similar to Alzheimer’s symptomatically, but is caused by repeated concussive and sub-concussive head trauma. The movie Concussion, released late 2015, is based […]

  • Capital Cube11 months ago

    ETFs with exposure to Aethlon Medical, Inc. : January 20, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)